GL-3, plasma

Alphabetical Test listing

GL-3, plasma-994

  
GL-3, plasma
  
994
  
LAB994
  
Fabrazyme biomarker
Fabry disease biomarker
  

Enzyme replacement therapy with Fabryzme results in a rapid and sustained decrease in plasma GL-3 levels and most patients. Periodic testing for GL-3 levels in plasma is recommended as part of the minimal schedule of assessments from the Fabry Registry prior to the start of treatment come every three months for the first 18 months of treatment and then every six months.

  
Plasma
  
  
1 mL
  
0.4 mL
  
  • Spin
  • Separate plasma into Labcorp transport vial
  • Freeze
  

Frozen (preferred) - 3 months

Freeze thaw cycles x 6

  

Clotted or severely hemolyzed plasma samples

  
Labcorp (504662) R-LC
  
One day per week
  
14 days
  

LC/MS

  

ug/mL

  
82542
  
08/10/2022
  
08/12/2022